Answers are grounded in this paper and cite their sources.
Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study that amended the ensuing drug utilization study (DUS) protocol, thus ascertaining fit-for-purpose data availability and quality, to better support regulatory decision-making. This retrospective, multicenter medical chart review in Germany and Italy, 6 months after Saxenda® (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS, collected patient data. The target study population included 100 initiators (25 Saxenda® and 25 Victoza® initiators in both Germany and Italy). Written informed consent was obtained before medical chart data extraction. Overall, 218 sites were contacted, with 39 Saxenda® initiators (33 in Italy; six in Germany) and 52 Victoza® initiators (31 in Italy; 21 in Germany). Patient records were obtained for all enrolled Saxenda® and Victoza® initiators in Italy and Germany; however, availability of individual study variables varied, with follow-up body weight showing the greatest degree of missingness among Saxenda® initiators. The pilot study indicated a poor enrollment feasibility of Saxenda® initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented in the ensuing DUS protocol to improve the collection of fit-for-purpose real-world data for regulatory decision-making.
No takes yet. Share an insight, caveat, or question.
Major‐Pedersen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: